Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 2/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 5/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3557511 | 0.89 | DDR1 (0.56) | DDR1PTK2NR1H2CYP2C9CYP2C19 | |
| SCHEMBL16380639 | 0.88 | DDR1 (0.47) | DDR1SLC9A1ADRA1DHTR2ASLC6A3 | |
| SCHEMBL19072901 | 0.88 | DDR1 (0.51) | DDR1PTK2NR1H2SLC9A1ADRA1D | |
| Hydrochloric Acid SCHEMBL3555518 | 0.87 | DDR1 (0.57) | DDR1NR1H2HTR2ACYP2C9CYP2C19 | |
| SCHEMBL3569954 | 0.84 | DDR1 (0.54) | DDR1HTR2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL19073475 | 0.83 | DDR1 (0.53) | DDR1NR1H2SLC9A1CYP3A4CYP2C9 | |
| SCHEMBL29958951 | 0.82 | DDR1 (0.49) | DDR1KIT | |
| SCHEMBL272847 | 0.81 | NR1H2 (0.63) | DDR1NR1H2KDM4EALDH1A1GAA | |
| SCHEMBL19178288 | 0.80 | DDR1 (0.49) | DDR1KDM4EALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL2707620 | 0.80 | NR1H2 (0.66) | DDR1NR1H2KDM4EALDH1A1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | claimed |
| US-20100113467-A1 | Organic Compounds | NOVARTIS AG | 2010-05-06 | — | — | US | claimed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | claimed |
| EP-2146964-A2 | ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE | Novartis Ag (CH) | 2010-01-27 | — | — | EP | claimed |
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | claimed |
| EP-1996558-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| EP-1996578-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| WO-2008125691-A2 | ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | claimed |
| WO-2008009487-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | claimed |
| WO-2007104538-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | claimed |
| US-8217045-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| US-8133886-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-03-13 | — | — | US | disclosed |
| US-20100113467-A1 | Organic Compounds | NOVARTIS AG | 2010-05-06 | — | — | US | disclosed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2146964-A2 | ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-1996578-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008125691-A2 | ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008009487-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | SLC8B1, MCU, GLS | DDR1 2964/4885PTK2 924/4885NR1H2 3262/4885 |
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | PHKG1, MAP3K20, CDK2 | DDR1 1457/4885PTK2 163/4885NR1H2 3005/4885 |
| US-20100113467-A1 | Organic Compounds | SLCO2A1, SLCO1B1, SLCO2B1 | DDR1 4853/4885PTK2 3959/4885NR1H2 440/4885 |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | MAP3K20, PHKG1, PHKG2 | DDR1 1404/4885PTK2 168/4885NR1H2 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.